Performance and Clinical Utility of a Commercial von Willebrand Factor Collagen Binding Assay for Laboratory Diagnosis of von Willebrand Disease

Popov, Joanna; Zhukov, Olga; Ruden, Susan; Zeschmann, Terry; Sferruzza, Anthony; Sahud, Mervyn A.

doi:10.1373/clinchem.2006.070730

Cited by 13 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ten addressed diagnostic test accuracy for types 2A and 2B 59,85-93 and 6 for type 2M. [87][88][89][90]92,93 For types 2A and 2B, the sensitivity of VWF:CB/VWF:Ag was 0.90 (95% CI, 0.78-0.96) and specificity was 0.95 (95% CI, 0.89-0.98), vs a sensitivity of 0.90 (95% CI, 0.90-0.99) and specificity of 0.97 (95% CI, 0.94-0.99) for multimers. For type 2M VWD, the sensitivity of VWF:CB/VWF:Ag was 0.98 (95% CI, 0.96-1.00) with a specificity of 0.99 (95% CI, 0.98-1.00), vs a sensitivity of 0.86 (95% CI, 0.73-0.98) and a specificity of 0.97 (95% CI, 0.94-0.99) for multimers.…”

Section: Remarkmentioning

confidence: 99%

ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease

et al. 2021

View full text Add to dashboard Cite

Background: von Willebrand disease (VWD) is the most common inherited bleeding disorder known in humans. Accurate and timely diagnosis presents numerous challenges. Objective: These evidence-based guidelines of the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) are intended to support patients, clinicians, and other health care professionals in their decisions about VWD diagnosis. Methods: ASH, ISTH, NHF, and WFH established a multidisciplinary guideline panel that included 4 patient representatives and was balanced to minimize potential bias from conflicts of interest. The Outcomes and Implementation Research Unit at the University of Kansas Medical Center (KUMC) supported the guideline-development process, including performing or updating systematic evidence reviews up to 8 January 2020. The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subsequently subject to public comment. Results: The panel agreed on 11 recommendations. Conclusions: Key recommendations of these guidelines include the role of bleeding-assessment tools in the assessment of patients suspected of VWD, diagnostic assays and laboratory cutoffs for type 1 and type 2 VWD, how to approach a type 1 VWD patient with normalized levels over time, and the role of genetic testing vs phenotypic assays for types 2B and 2N. Future critical research priorities are also identified.

show abstract

Section: Remarkmentioning

confidence: 99%

ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease

et al. 2021

View full text Add to dashboard Cite

show abstract

“…These tests, summarized in Table 1, are prothrombin time, coagulation factor VIII activity (FVIII:C), vWF ristocetin cofactor activity assay (vWF:RCo), vWF antigen (vWF: Ag), vWF:RCo/Ag ratio as previously described, 8 vWF collagenbinding activity (vWF:CBA), vWF:CBA/Ag ratio, 9 and ADAMTS 13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) activity (Genprobe, San Diego, CA) following the manufacturer's instructions.…”

Section: Coagulation Laboratory Testingmentioning

confidence: 99%

Pilot investigation of a novel testing strategy for bleeding in ventricular assist device recipients

Joyce

Crow

et al. 2012

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

“…VWF:CB is a quantitative and qualitative assay which measures, typically by enzyme-linked immunosorbent assay (ELISA), the ability of VWF to bind collagen and is highly sensitive to the presence of high molecular weight VWF multimers. 6 Recently many reports have focused on the development of new tests for the diagnosis of VWD [6][7][8][9][10][11] and for monitoring the effects of treatments. 6,12 Indeed, patients with VWD are often treated with desmopressin (1-deamino-8-arginine vasopressin, DDAVP), a synthetic analog of the antidiuretic hormone vasopressin, which increases the plasma levels of factor VIII (FVIII) and VWF by 3 to 5-fold.…”

mentioning

confidence: 99%